Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $18.75

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $18.75.

A number of equities analysts have recently commented on the stock. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. RODMAN&RENSHAW raised shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, December 20th. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock. Finally, Canaccord Genuity Group boosted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Atara Biotherapeutics Price Performance

NASDAQ ATRA opened at $16.19 on Tuesday. The company has a fifty day moving average of $12.47 and a two-hundred day moving average of $9.91. The company has a market capitalization of $93.25 million, a PE ratio of -0.63 and a beta of 0.51. Atara Biotherapeutics has a 1 year low of $6.50 and a 1 year high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period last year, the company earned ($16.50) earnings per share. On average, research analysts expect that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in ATRA. State Street Corp raised its holdings in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. FMR LLC raised its holdings in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Atara Biotherapeutics in the 2nd quarter valued at about $79,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics during the second quarter valued at approximately $53,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.